Navigation Links
Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Date:2/18/2011

conducted after 468 deaths.

An independent Data and Safety Monitoring Board (DSMB) will assess blinded safety measures and demographics at regular intervals throughout the study or as determined by the DSMB chair. The DSMB will also review interim irPFS data, unblinded at the group level, after 200 irPFS events. At the time of interim sample size review, the DSMB may recommend changes to the sample size or early termination of the study for efficacy or safety reasons as detailed in the protocol.

Key DatesFirst patient recruited Q3 2011

Interim data analysis* Q4 2012 - 1Q 2013

Final data analysis * Q4 2013 - 1Q 2014

*As an event driven study with adaptable design to have the flexibility after interim analysis to adjust patient size and study duration. Precise timelines are driven by these events of study patient progression free survival and/or overall survival and this can only be indicative.

Study SummaryThe purpose of this study is to determine whether CVac™ is effective in the treatment of Patients With Epithelial Ovarian Cancer (EOC) Following Optimal Debulking Surgery and First-line Chemotherapy as assessed by progression free survival or overall survival.

EndpointsPrimary Objectives

  • To assess the efficacy, in terms of immune-related progression-free survival (irPFS), of CVac™ as compared with placebo for maintenance treatment in patients with epithelial ovarian cancer (EOC) following optimal debulking surgery and first-line chemotherapy
  • To assess the efficacy, in terms of overall survival (OS), of CVac as compared with placebo for maintenance treatment in patients with EOC following optimal debulking surgery and first-line chemotherapy.

  • Secondary Objectives

  • To assess the safety and tolerability of CVac™ as compared with placebo
  • To assess health-related quality of life (QoL) related to CVac treatment as compared with plac
    '/>"/>

  • SOURCE Prima BioMed Ltd
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
    2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
    3. New Research May Lead to Earlier Diagnosis and Treatment of Primary Biliary Cirrhosis in Families
    4. ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
    5. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
    6. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
    7. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
    8. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
    9. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
    10. Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM)
    11. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/22/2014)... 2014  - MediaLINC ... Today Lincor announced general availability of MediaLINC ... a range of education, entertainment and clinical content direct ... http://photos.prnewswire.com/prnh/20140822/702945) , " Lincor has ... patient engagement to bedside smart devices, " comments ...
    (Date:8/22/2014)... , Aug. 22, 2014  Landauer, Inc. (NYSE: ... environmental radiation measurement and monitoring, outsourced medical physics services ... William E. Saxelby , its President and Chief ... Chief Executive Officer and as a member of the ... He will be replaced on an interim basis by ...
    (Date:8/22/2014)... , Aug. 22, 2014  WaferGen Bio-systems, Inc. ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... expected to begin trading on The NASDAQ Stock Market ...
    Breaking Medicine Technology:Lincor Unveils Next Generation TV-based Patient Engagement Solution 2Landauer, Inc. Announces Executive Management Change 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
    ... Dec. 29, 2010 Reportlinker.com announces that a new ... Mammography World Markets ... poised for a major new phase of growth fueled ... the computer and digital areas and the higher interest ...
    ... (Nasdaq: OMER ), a biopharmaceutical company ... on inflammation and disorders of the central nervous ... clinical trial of OMS201, the Company,s urological PharmacoSurgery™ ... an anti-inflammatory agent and a smooth muscle relaxant, ...
    Cached Medicine Technology:Reportlinker Adds Mammography World Markets 2Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy 2Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy 3
    (Date:8/22/2014)... can be slowed and some of its symptoms ... in pomegranate. Also, the painful inflammation that ... disease could be reduced, according to the findings ... Huddersfield scientist Dr Olumayokun Olajide, who specialises in ... a new phase of research can explore the ...
    (Date:8/22/2014)... Oncology (ESMO), the leading pan-European organisation representing medical ... outstanding individuals receiving the Society,s esteemed annual awards. ... Heikki Joensuu and Peter Boyle on the occasion ... Spain. , Carsten Bokemeyer will receive the ESMO ... of cancer discovery into real benefit at patient ...
    (Date:8/22/2014)... The New Jersey Institute for Food, Nutrition ... of New Jersey has joined forces with ChopChop ... young people about health and nutrition in a new ... organizations. , The partnership will encompass quarterly custom editions ... video communications. ChopChop Magazine features plenty of child-friendly ...
    (Date:8/22/2014)... very low levels of nicotine may reduce addiction ... a new study from the University of Waterloo. ... Cancer Epidemiology monitored the smoking behaviours ... types of cigarettes with markedly reduced nicotine levels. ... brandsall of which have very similar levels of ...
    (Date:8/22/2014)... AcousticSheep LLC participated in one of the largest running ... Run – otherwise known as the “Happiest 5K on the Planet.” ... participants from Erie, surrounding areas, and even from as far away ... largest running events put on in Erie, PA yet – the ... the Planet.” The event took place on August 9, 2014 and ...
    Breaking Medicine News(10 mins):Health News:Research underway to create pomegranate drug to stem Alzheimer's and Parkinson's 2Health News:ESMO honours outstanding oncology professionals 2Health News:ESMO honours outstanding oncology professionals 3Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 2Health News:New Jersey Institute for Food, Nutrition & Health to Launch Innovative Partnership with Award-Winning Children’s Anti-Obesity Organization, ChopChop Kids 3Health News:Smokers consume same amount of cigarettes regardless of nicotine levels 2Health News:RunPhones® Reveals Erie, PA Enthusiasm Impressed Color Run Director 2Health News:RunPhones® Reveals Erie, PA Enthusiasm Impressed Color Run Director 3
    ... getting action from Cardinal George and Public Official ... ... years ago, health care activist,Joe Novak -- during a private audience with ... of not-for-profit health,care systems, especially those that are Catholic., "Three years ...
    ... were implemented in poor countries, cases of stunting among under ... up to a quarter, according to new research being published ... Hygiene & Tropical Medicine, is one of the authors of ... and Child Undernutrition Series, which is being launched this week. ...
    ... 17 Fleishman-Hillard Inc. today pledged,$250,000 in global ... fight to reduce micronutrient deficiencies in developing countries.,Adopting ... Food and,Agribusiness Practice will provide communications strategy and ... of flour standard,practice around the world., One-third ...
    ... Pill timed to body,s rhythms, helps with morning joint ... A modified-release form of the steroid prednisone is ... joint stiffness in people with rheumatoid arthritis, a new ... Berlin studied 288 people with active rheumatoid arthritis. Half ...
    ... Texas In the last few years, personalized medicine ... customize treatment for a particular patient has emerged ... , Therapy guided by genetic testing has proven highly ... and lung cancer. Similar personalized therapies are on the ...
    ... School of Medicine discovered that proteins carrying chemical cargo ... tau protein, which plays an important role in Alzheimers ... cargo towards opposite ends of tracks called microtubules. Tau ... speed bump to regulate protein traffic, the group found. ...
    Cached Medicine News:Health News:Ad Campaign Targets Abuses by Not-For-Profits 2Health News:One-third of stunting and a quarter of deaths among under 3s in poor countries could be prevented 2Health News:Fleishman-Hillard Names FFI Global Cause for 2008 2Health News:Modified-Release Prednisone May Ease Rheumatoid Arthritis 2Health News:Discovery opens door to 'personalized' asthma therapy 2Health News:Alzheimer's molecule is a smart speed bump on the nerve-cell transport highway 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: